Gsk (GSK) Cash & Current Investments (2009 - 2026)

Gsk (GSK) has 18 years of Cash & Current Investments data on file, last reported at $4.3 billion in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 15.36% year-over-year to $4.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.3 billion (down 15.36% YoY), and the FY2025 full-year result was $4.7 billion, changed 0.47% from the prior year.
• Cash & Current Investments was $4.3 billion for Q2 2026 at Gsk, down from $4.4 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $8.3 billion in Q2 2022 to a low of $536.7 million in Q1 2022.
• A 5-year average of $4.3 billion and a median of $4.3 billion in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 92.2% in 2022 and surged 582.79% in 2023, its largest moves.
• Gsk's Cash & Current Investments stood at $4.6 billion in 2022, then dropped by 17.09% to $3.8 billion in 2023, then rose by 24.05% to $4.7 billion in 2024, then fell by 0.87% to $4.7 billion in 2025, then decreased by 8.34% to $4.3 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $4.3 billion in Q2 2026, $4.4 billion in Q1 2026, and $4.7 billion in Q4 2025.